We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSLN
RNS Number : 3996A
Silence Therapeutics PLC
28 December 2017
Further Partial Disposal of Arrowhead common shares
28 December 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has sold a further part of its holding of common shares in Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) ("Arrowhead").
As per an RNS dated 13 January 2017, Silence had purchased 6,831,359 common shares of Arrowhead for a total consideration of $11.3 million (GBP9.2 million at an exchange rate of GBP1=$1.234), then representing 9.21% of Arrowhead. At the Company's last balance sheet date (30 June 2017) this shareholding was marked-to-market and valued at GBP8.55 million as an available-for-sale financial asset.
Since the RNS dated 11 December 2017, Silence has sold a further 2,317,693 common shares for an average selling price of $3.60. The Company still holds 472,509 common shares which represents 0.63% of Arrowhead.
In total, the Company has now sold 6,358,850 common shares on the open market realising proceeds of $23.0 million (GBP17.2 million). The average purchase price per common share was $1.65 and the average selling price of the 6,358,850 common shares sold was $3.62. The total profit recorded is therefore $12.5 million, or GBP8.7 million. The Company will use the proceeds from the sale of the common shares to fund the Company's working capital requirements.
Silence has determined it may be advantageous to liquidate portions or all of its remaining holding of Arrowhead common shares from time to time in an orderly manner consistent with prudent management of its investment.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 Ali Mortazavi, Chief Executive 3457 6900 Officer David Ellam, Chief Financial Officer Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20 and Broker) 7418 8900 James Steel/Oliver Jackson Media Enquiries: Tel: +44 (0) Optimum Strategic Communications 20 3714 1788 Mary Clark/ Eva Haas/ Hollie Vile
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DISTRBJTMBITTAR
(END) Dow Jones Newswires
December 28, 2017 02:00 ET (07:00 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions